Azelaic acid 10% vs 20%: what the evidence does and does not transfer

Azelaic acid is one of the most searched skincare ingredients in the markets this platform covers, and one of the most consistently misunderstood. The confusion is almost always about concentration, and it is a confusion that the evidence cannot resolve in the way people hope.

The rule that prevents most of the confusion

Evidence for 20% prescription azelaic acid does not transfer to 10% cosmetic formulations.

That is a statement about evidence transfer, not a claim that one product is good and another is bad. The 10% cosmetic formulation is a different product, at a different concentration, with different regulatory status, and it cannot borrow the evidence of the 20% prescription formulation. If a review article or a shop assistant pairs the two, the pairing is the problem.

What the fetched review supports

Topical retinoids, hydroxy acids and broad-spectrum sunscreen carried the greatest evidence support in the fetched systematic review of PIH treatment evidence. Azelaic acid appears in the same fetched review's documented treatment evidence, at prescription strength (20%), with the full-text algorithms not extracted in the research session.

So the honest position is: there is real clinical evidence for azelaic acid as a treatment for post-inflammatory hyperpigmentation, it is strongest at prescription strength, and the study designs behind it were not fully extracted into this platform's research.

What this means when you read an ingredient list

The same separation applies to every ingredient in our library. Ingredient-level evidence ratings describe what the research says about the ingredient. They say nothing about whether a particular bottle on a particular shelf delivers the concentration, the formulation or the stability the research relied on.

Our ingredient pages keep those two things apart deliberately: the evidence rating and note sit alongside a concentration caveat, and the products linked from an ingredient page are shown with their own verification status and per-market listings. A 10% azelaic product in our library carries its price, retailer, availability, provenance and the date those were checked. It does not carry the clinical evidence of 20% azelaic, and it is never shown as if it does.

Where the 10% and 20% versions actually sit

Both strengths are recorded in our four markets, and availability differs by country. In Nigeria the recorded range runs from a prescription-strength 20% product through to premium 10% formulations. In South Africa and Ghana the recorded listings are 10% formulations. Kenya's records come through marketplace listings, where the recorded collection page does not list azelaic acid as a product line — a search-page artefact rather than evidence of absence, which is exactly why a dedicated search was run to correct it.

You can see every listing, its price, its retailer and the date it was checked in the product library.

The safety line, plainly

Azelaic acid 20% is a prescription-strength treatment. It requires appropriate medical supervision, and it is not a routine first-line recommendation that belongs in a general skincare routine. If a licensed pharmacist or doctor advises it, follow their instructions rather than a product page — including ours.

Seek medical evaluation for worsening melasma, post-inflammatory hyperpigmentation that has not responded after three to six months of consistent care, and anything suspected to be skin cancer.